Ketolog

Each tablet of Ketolog contains: Calcium-4-methyl-2-oxo-valerate (α-ketoanalogues to leucine, calcium salt) 101 mg, calcium-3-methyl-2-oxo-butyrate (α-ketoanalogues to valine, calcium salt) 86 mg, calcium-2-oxo-3-phenylpropionate (α-ketoanalogues to phenylalanine, calcium salt) 68 mg, calcium-3-methyl-2-oxo-valerate (α-ketoanalogues to isoleucine, calcium salt) 67 mg, calcium-DL-2-hydroxy-4 (methylthio) butyrate (α-hydroxyanalogue to methionine, calcium salt) 59 mg, L-lysine-acetate USP 105 mg, L-threonine USP 53 mg, L-histidine USP 38 mg, L-tyrosine USP 30 mg, L-tryptophan USP 23 mg, total nitrogen content 36 mg, calcium 1.25 mmol equivalent to 0.05 g.

Prevention and therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection with limited protein food of ≤40 g/day (for adults).

Adults (70 kg/body weight): 4-8 tablets 3 times daily during meals.

Administration: For oral use. Tablets may be taken during meals; should be swallowed whole.

Duration of Use: Ketolog tablets are given as long as the GFR is between 5 and about 15 mL/min. Simultaneously for adults, food should contain ≤40 g/day of protein ie, generally in patients with glomerular filtration rate (GFR) between 5 and about 15 mL/min.

Hypercalcemia, disturbed amino acid metabolism.

In case of hereditary phenylketonuria, it has to be taken into account that Ketolog contains phenylalanine.

Simultaneous administration of medicaments containing calcium (eg, acetolyte) may lead to pathological increases of the serum calcium level or intensification. As the uremic symptoms improve under Ketolog, a possible administration of aluminum hydroxide should be reduced. Pay attention to a reduction of serum phosphate.

Do not take drugs together with Ketolog that form sparingly soluble compounds with calcium (eg, tetracyclines) in order not to interfere with absorption.

Hypercalcemia may develop.